| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -20,379 | -11,400 |
| Depreciation | 19 | 13 |
| Amortization of intangible asset | 1,036 | 687 |
| Share-based compensation expense | 170 | 117 |
| Interest on short-term investments | 0 | 0 |
| Amortization of debt discount and deferred financing costs | 194 | 194 |
| Interest on notes - non-cash-Exchangeable Senior Subordinated Notes Due Two Thousand Twenty Five | 88 | 88 |
| Financing transaction costs included in financing activities | 0 | - |
| Interest on notes - non-cash-Promissory Note | 1,415 | 853 |
| Adjustments to fair value of derivatives | -1,807 | -1,134 |
| Other | -1,820 | -940 |
| Accounts receivable | 448 | - |
| Prepaid expenses and other current assets | 2,196 | 1,212 |
| Inventory | 1,149 | 948 |
| Accounts payable | 326 | 938 |
| Accrued expenses | 2,642 | 1,299 |
| Income taxes | -35 | 54 |
| Other liabilities | -568 | -568 |
| Net cash used in operating activities | -15,258 | -7,811 |
| Purchases of property and equipment | 14 | 2 |
| Purchases of short-term investments | 0 | 0 |
| Proceeds from sale of short-term investments | 0 | 0 |
| Net cash (used in) / provided by investing activities | -14 | -2 |
| Repayment of exchangeable notes | 14,745 | 14,745 |
| Proceeds from issuance of ordinary shares, net of transaction costs | 16,909 | 11,477 |
| Net cash provided by financing activities | 2,164 | -3,268 |
| Effect of exchange rates on cash and cash equivalents | -20 | -18 |
| Net (decrease) / increase in cash, cash equivalents and restricted cash | -13,128 | -11,099 |
| Cash and cash equivalents at beginning of period | 24,159 | - |
| Cash and cash equivalents at end of period | 11,031 | - |
Iterum Therapeutics plc (ITRM)
Iterum Therapeutics plc (ITRM)